ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting ARIAD Pharmaceuticals, Inc. today announced that updated clinical data from a fully enrolled Phase 1 trial of its investigational, pan-BCR-ABL inhibitor, ponatinib, will be offered at the 52nd Annual Getting together with of the American Culture of Hematology being kept in Orlando, Florida, 4-7 December, 2010. These Phase 1 findings in sufferers with resistant and refractory chronic myeloid leukemia will be featured within an oral presentation and will also be highlighted in a webcast investor meeting being held at ASH. The schedule and locations for the trader meeting and oral presentation session are listed below:..Hege Tunstad, a spokeswoman at the university in Trondheim, stated May-Britt Moser needed one minute to cry and consult with her group when she heard bout the prize. The Nobel Assembly stated understanding of the brain’s positioning system may help us understand the system underpinning the devastating spatial memory space loss that affects people who have Alzheimer’s disease. The discoveries have opened new avenues for understanding cognitive functions such as memory also, planning and thinking, it said.